• CEO Lisa Anson discussed £25.5m raise to drive forward key programmes

    Read more
  • Lisa talks through our strategy at the Proactive One2One Virtual Biotech Forum 29th October

    Read more
  • Interview with Lisa Anson in The Sunday Times

    Read more
  • Redx Pharma PLC’s Lisa Anson updates on lead asset RXC004 and increased investment by Redmile

    Read more
  • Video interview with Lisa Anson following news of first cohort of patients successfully dosed with RXC004 in Phase 1/2 Study

    Read more
  • Video interview with Lisa Anson following sale of pan-RAF inhibitor programme to Jazz Pharmaceuticals

    Read more
  • Video interview with Lisa Anson following Interim Results confirming start of phase I study of lead drug RXC004

    Read more
  • Redx Pharma CEO Lisa Anson appears in the Telegraph’s International Women’s Day feature

    Read more
  • Lisa Anson talks about new in vivo data indicating the broad potential of ROCK2 inhibitor in fibrosis (Video)

    Read more
  • Redx Pharma receives approval to re-commence clinical trial of RXC004 (Proactiveinvestors.co.uk)

    Read more